Placental Growth Factor

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 8040 Experts worldwide ranked by ideXlab platform

Matts Olovsson - One of the best experts on this subject based on the ideXlab platform.

Deirdre Allegranza - One of the best experts on this subject based on the ideXlab platform.

Alison M Stuebe - One of the best experts on this subject based on the ideXlab platform.

  • midgestation maternal serum 25 hydroxyvitamin d level and soluble fms like tyrosine kinase 1 Placental Growth Factor ratio as predictors of severe preeclampsia
    Hypertension, 2011
    Co-Authors: Padmashree Chaudhury Woodham, Julia E Brittain, Arthur M Baker, Leann D Long, Sina Haeri, Carlos A Camargo, Kim A Boggess, Alison M Stuebe
    Abstract:

    Recent studies have shown that low serum 25-hydroxyvitamin D (25[OH]D) level is a risk Factor for preeclampsia. The clinical significance of in vitro findings that vitamin D regulates vascular endothelial Growth Factor production is unclear. We sought to determine whether there is an association between midgestation serum 25(OH)D levels and angiogenic Factor activity and to compare their predictive value for the development of severe preeclampsia. We conducted a nested case-control study of women with severe preeclampsia (n=41) versus women with uncomplicated term birth (n=123) who had second trimester genetic screening (15–20 weeks). Using banked frozen serum, we measured levels of 25(OH)D, vascular endothelial Growth Factor, soluble fms-like tyrosine kinase 1, and Placental Growth Factor and compared their correlations and predictive values. We found no correlation between serum 25(OH)D and angiogenic Factors levels. 25(OH)D alone was comparable to vascular endothelial Growth Factor and soluble fms-like tyrosine kinase 1/Placental Growth Factor ratio as a predictive marker for severe preeclampsia. A composite of both 25(OH)D level and soluble fms-like tyrosine kinase 1/Placental Growth Factor ratio was more predictive than either alone (area under curve: 0.83 versus 0.74 and 0.67, respectively). In conclusion, combining midpregnancy 25(OH)D level with soluble fms-like tyrosine kinase 1/Placental Growth Factor ratio provides a better prediction for the development of severe preeclampsia.

Gordon C S Smith - One of the best experts on this subject based on the ideXlab platform.

Bahaeddine M Sibai - One of the best experts on this subject based on the ideXlab platform.

  • reductions of vascular endothelial Growth Factor and Placental Growth Factor concentrations in severe preeclampsia
    American Journal of Obstetrics and Gynecology, 2000
    Co-Authors: Jeffrey Livingston, Robert R H Chin, Bassam Haddad, Elizabeth T Mckinney, Robert Ahokas, Bahaeddine M Sibai
    Abstract:

    Objective: The aim of this study was to determine whether plasma concentrations of vascular endothelial Growth Factor and Placental Growth Factor are altered in women with severe preeclampsia. Study Design: We performed a case-control study to compare plasma concentrations of vascular endothelial Growth Factor and Placental Growth Factor between women with severe preeclampsia and normotensive women admitted for delivery. Twenty-one women with severe preeclampsia were matched for gestational age and ethnicity with 21 normotensive women. Vascular endothelial Growth Factor and Placental Growth Factor concentrations were measured with a specific antigen-capture enzyme-linked immunosorbent assay. Results: Women with severe preeclampsia demonstrated significantly lower plasma concentrations of both vascular endothelial Growth Factor (6.36 ± 3.96 pg/mL vs 18.65 ± 5.98 pg/mL; P <.0001) and Placental Growth Factor (138 ± 119 pg/mL vs 531 ± 340 pg/mL; P <.0001) than did women with normotensive pregnancy. Logistic regression analysis showed an independent association between plasma vascular endothelial Growth Factor concentration and plasma Placental Growth Factor concentration and preeclampsia. Conclusion: Patients with severe preeclampsia had decreased maternal serum concentrations of both vascular endothelial Growth Factor and Placental Growth Factor. (Am J Obstet Gynecol 2000;183:1554-7.)

  • Reductions of vascular endothelial Growth Factor and Placental Growth Factor concentrations in severe preeclampsia
    American Journal of Obstetrics and Gynecology, 2000
    Co-Authors: Jeffrey Livingston, Robert R H Chin, Bassam Haddad, Elizabeth T Mckinney, Robert Ahokas, Bahaeddine M Sibai
    Abstract:

    Objective: The aim of this study was to determine whether plasma concentrations of vascular endothelial Growth Factor and Placental Growth Factor are altered in women with severe preeclampsia. Study Design: We performed a case-control study to compare plasma concentrations of vascular endothelial Growth Factor and Placental Growth Factor between women with severe preeclampsia and normotensive women admitted for delivery. Twenty-one women with severe preeclampsia were matched for gestational age and ethnicity with 21 normotensive women. Vascular endothelial Growth Factor and Placental Growth Factor concentrations were measured with a specific antigen-capture enzyme-linked immunosorbent assay. Results: Women with severe preeclampsia demonstrated significantly lower plasma concentrations of both vascular endothelial Growth Factor (6.36 ± 3.96 pg/mL vs 18.65 ± 5.98 pg/mL; P

Related terms

Placental Growth Factor - 15 days free trial to Access Experts & Abstracts